Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb

Evotec SE has achieved significant scientific progress within its strategic neuroscience collaboration with Bristol Myers Squibb. This milestone has triggered a research payment of USD 20 million to Evotec. The target-based programme has advanced to late pre-clinical development. This development contributes to the promising pipeline of neurodegeneration programmes generated by the partnership.

Initiated in December 2016, the collaboration aims to identify treatments for various neurodegenerative diseases. Approved drugs largely focus on symptom management, highlighting the need for therapies that can slow or prevent disease progression.

In September 2021, Bristol Myers Squibb in-licensed EVT8683 as BMS-986419. Following a successful Phase I study, a Phase II study is planned for 2024. The partnership was extended in March 2023 for an additional eight years.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, emphasized the progress in the pipeline and the commitment to patient care. The partnership continues to advance critical programmes aimed at delivering new therapeutic options for neurological disorders.